Centene: Be Greedy When Others Are Fearful
Centene's stock is deeply undervalued after a 60% drop, with key valuation multiples 50%-70% below historical averages. Despite 2025 headwinds and EPS guidance cuts, Centene remains profitable, well-diversified, and financially stable with strong liquidity. Long-term demographic trends and Centene's history of resilience support a sharp EPS rebound in 2026 and 2027.
Centene Faces HBR Pressures: Will Scale Support Stability?
CNC's rising HBR, driven by higher medical costs and policy shifts, pressures margins as it leans on scale and efficiency for stability.
Is CNC Banking on Membership Growth to Boost Scale & Profitability?
Centene's growing membership base boosts revenue scale and operational efficiency, even as medical inflation puts pressure on margins.
One Big Beautiful Bill Act: A Boon or Bane for Centene?
CNC faces both risk and reward from the One Big Beautiful Bill Act as Medicaid cuts collide with digital reform gains.
Centene Loses 57% YTD, Incurs Loss in Q2: How to Play the Stock
CNC plunges 57% YTD after its first quarterly loss in over a decade, with analysts slashing 2025 earnings outlook by 70%.
Centene's Bottom May Already Be Here - Risk Mitigation In Process
CNC has offered FY2025 adj EPS range at between $1.25 (-82.5% YoY) and $1.75 (-75.5% YoY), as medical costs rise drastically and higher morbidity sign-ups replace a healthier base. These have directly triggered the drastically lower consensus forward estimates, with the healthcare providers expected to report impacted, new normal profit margins. Despite so, readers must note that CNC is already engaging on risk mitigation while driving improved profitability through rate adjustments from 2026 onwards.
Centene's Worst Quarter In Years Could Be A Gift
Centene's Q2 results were ugly but better than feared, with losses largely expected and a visible path to recovery emerging. Management is aggressively addressing ACA and Medicaid margin pressures, with rate adjustments and reratings expected to restore profitability by 2026. Valuation remains highly attractive, trading at under 7x PE, offering potential for the stock to double as earnings rebound and multiples normalize.
Time To Buy Centene Stock?
Centene (NYSE:CNC) recently reported a surprise loss of $0.16 per share for Q2, significantly missing analyst expectations of $0.23 per share. This downturn is primarily attributed to a continued increase in medical costs for government-backed insurance plans, evidenced by a 540 basis point year-over-year surge in its health benefit ratio to 93% in Q2.
Centene Corporation (CNC) Q2 2025 Earnings Call Transcript
Centene Corporation (NYSE:CNC ) Q2 2025 Earnings Conference Call July 25, 2025 8:30 AM ET Company Participants a - Corporate Participant v - Corporate Participant Andrew Lynn Asher - Chief Financial Officer Jennifer Lynch Gilligan - Senior Vice President of Investor Relations Sarah M. London - CEO & Director Conference Call Participants Albert J.
Medical Expenses Erode Centene's Bottom Line in Rare Q2 Earnings Miss
CNC reports rare Q2 loss amid surging medical costs, lower investment and other income despite strong revenue growth.
Centene Stock Showing Signs of Life After Revenue Beat
Centene Corp (NYSE:CNC) stock is 3.9% higher to trade at $27.75 this morning, even after the managed healthcare company reported an adjusted second-quarter loss of 16 cents per share, steeper than the 11 cents per share projected.
Centene (CNC) Reports Q2 Loss, Tops Revenue Estimates
Centene (CNC) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of $0.68. This compares to earnings of $2.42 per share a year ago.
